Gabapentin (All indications) updated on 04-22-2025

Hypospadias

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S19321
R81887		 Kim (Controls exposed to LTG) (Gabapentin) (Indications NOS), 2026 Hypospadias 1st trimester population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.91 [0.20;18.37] C
excluded (control group) 		3/1,131   1/718 4 1,131
ref
S19313
R81786		 Kim (Controls unexposed, NOS) (Gabapentin) (Indications NOS), 2026 Hypospadias 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 1.80 [0.45;7.21] 3/1,131   2,427/2,489,078 2,430 1,131
ref
S10033
R36117		 Blotière (Controls exposed to Lamotrigine, sick) (Other indications), 2019 Hypospadias 1st trimester retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No Controls: mixed indications 1.17 [0.14;9.57] C
excluded (control group) 		1/365   7/2,997 8 365
ref
S10034
R36140		 Blotière (Controls unexposed NOS) (Other indications), 2019 Hypospadias 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 1.53 [0.21;10.87] C 1/365   3,371/1,875,733 3,372 365
ref
S8493
R27901		 Morrow (Controls exposed to Lamotrigine, sick), 2006 Hypospadias/genitourinary tract defects 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 1.62 [0.09;29.34] C 0/31   6/647 6 31
ref
Total 3 studies 1.69 [0.59;4.86] 5,808 1,527
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Kim (Controls unexposed, NOS) (Gabapentin) (Indications NOS), 2026Kim, 2026 1 1.80[0.45; 7.21]2,4301,13158%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Blotière (Controls unexposed NOS) (Other indications), 2019Blotière, 2019 2 1.53[0.21; 10.87]3,37236529%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Morrow (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 3 1.62[0.09; 29.34]63113%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 0% 1.69[0.59; 4.86]5,8081,5270.55.01.0ROB: A: confounding, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, NOS) (Gabapentin) (Indications NOS; 2: Controls unexposed NOS) (Other indications; 3: Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.69[0.59; 4.86]5,8081,5270%NAKim (Controls unexposed, NOS) (Gabapentin) (Indications NOS), 2026 Blotière (Controls unexposed NOS) (Other indications), 2019 Morrow (Controls exposed to Lamotrigine, sick), 2006 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.70[0.55; 5.29]5,8021,4960%NAKim (Controls unexposed, NOS) (Gabapentin) (Indications NOS), 2026 Blotière (Controls unexposed NOS) (Other indications), 2019 2 exposed to other treatment, sickexposed to other treatment, sick 1.62[0.09; 29.34]631 -NAMorrow (Controls exposed to Lamotrigine, sick), 2006 1 Tags Adjustment   - No  - No 1.55[0.31; 7.89]3,3783960%NABlotière (Controls unexposed NOS) (Other indications), 2019 Morrow (Controls exposed to Lamotrigine, sick), 2006 2   - Yes  - Yes 1.80[0.45; 7.20]2,4301,131 -NAKim (Controls unexposed, NOS) (Gabapentin) (Indications NOS), 2026 1 All studiesAll studies 1.69[0.59; 4.86]5,8081,5270%NAKim (Controls unexposed, NOS) (Gabapentin) (Indications NOS), 2026 Blotière (Controls unexposed NOS) (Other indications), 2019 Morrow (Controls exposed to Lamotrigine, sick), 2006 30.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 10033, 19321

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.70[0.55; 5.29]5,8021,4960%NAKim (Controls unexposed, NOS) (Gabapentin) (Indications NOS), 2026 Blotière (Controls unexposed NOS) (Other indications), 2019 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.50[0.39; 5.84]181,5270%NAKim (Controls exposed to LTG) (Gabapentin) (Indications NOS), 2026 Blotière (Controls exposed to Lamotrigine, sick) (Other indications), 2019 Morrow (Controls exposed to Lamotrigine, sick), 2006 30.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Veroniki a (MA) (All indications) (Hypospadias)Veroniki a (MA) (All indications) (Hypospadias) Out of scale4096.00[36.18; 193000.00]NA-Wwhatever (meta-analysis)T11st trimesterstudies TTT1 Veroniki a (NMA) (All indications) (Hypospadias)Veroniki a (NMA) (All indications) (Hypospadias) Out of scale16.54[2.50; 121.70]NA-Wwhatever (meta-analysis)T11st trimesterstudies TTT-9 metaPregmetaPreg 1.69[0.59; 4.86]0%1,527----Kim (Controls unexposed, NOS) (Gabapentin) (Indications NOS), 2026 Blotière (Controls unexposed NOS) (Other indications), 2019 Morrow (Controls exposed to Lamotrigine, sick), 2006 30.510.01.0